Surrozen (SRZN) Non-Current Assets (2020 - 2026)
Surrozen (SRZN) posted quarterly Non-Current Assets of $6.8 million for Q1 2026, down 23.34% year-over-year from $8.8 million in Q1 2025, and down 5.68% quarter-over-quarter from $7.2 million in Q4 2025.
Surrozen (SRZN) Non-Current Assets (2020 - 2026) Analysis & Trends
Surrozen's Non-Current Assets history runs 7 years deep, the most recent figure standing at $6.8 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 23.34% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $30.6 million (up 24.8% YoY), while the FY2025 annual figure was $7.2 million, down 24.83% from the prior year.
- Non-Current Assets for Q1 2026 stood at $6.8 million, down from $7.2 million in the prior quarter.
- The five-year high for Non-Current Assets was $22.0 million in Q1 2022, with the low at $2.7 million in Q3 2024.
- The 5-year median for Non-Current Assets is $7.2 million (2025), against an average of $7.8 million.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets plunged 89.89% in 2022, then surged 201.84% in 2025.
- Surrozen's Non-Current Assets stood at $8.1 million in 2022, then tumbled by 39.14% to $4.9 million in 2023, then soared by 92.7% to $9.5 million in 2024, then fell by 24.83% to $7.2 million in 2025, then slipped by 5.68% to $6.8 million in 2026.
- Business Quant data shows SRZN's Non-Current Assets at $6.8 million in Q1 2026, $7.2 million in Q4 2025, and $8.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | 6.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.21 Mn |
| Mar 31, 2026 | 6.76 Mn |
| Dec 31, 2025 | 7.17 Mn |
| Sep 30, 2025 | 8.19 Mn |
| Jun 30, 2025 | 8.46 Mn |
| Mar 31, 2025 | 8.82 Mn |
| Dec 31, 2024 | 9.54 Mn |
| Sep 30, 2024 | 2.71 Mn |
| Jun 30, 2024 | 3.43 Mn |
| Mar 31, 2024 | 4.70 Mn |
| Dec 31, 2023 | 4.95 Mn |
| Sep 30, 2023 | 5.62 Mn |
| Jun 30, 2023 | 6.42 Mn |
| Mar 31, 2023 | 7.17 Mn |
| Dec 31, 2022 | 8.13 Mn |
| Sep 30, 2022 | 8.72 Mn |
| Jun 30, 2022 | 9.31 Mn |
| Mar 31, 2022 | 21.98 Mn |
| Dec 31, 2021 | 31.99 Mn |
| Sep 30, 2021 | 36.63 Mn |